Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Research & Development: 2009-2025

Historic Research & Development for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $1.3 million.

  • Cumberland Pharmaceuticals' Research & Development fell 4.04% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 10.89%. This contributed to the annual value of $4.8 million for FY2024, which is 17.45% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Research & Development stood at $1.3 million, which was down 14.64% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Research & Development peaked at $1.9 million during Q3 2023, and registered a low of $1.1 million during Q2 2024.
  • Its 3-year average for Research & Development is $1.3 million, with a median of $1.3 million in 2024.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Research & Development skyrocketed by 38.79% in 2022 and then crashed by 37.21% in 2023.
  • Quarterly analysis of 5 years shows Cumberland Pharmaceuticals' Research & Development stood at $1.6 million in 2021, then dropped by 12.83% to $1.4 million in 2022, then decreased by 10.04% to $1.3 million in 2023, then increased by 2.21% to $1.3 million in 2024, then fell by 4.04% to $1.3 million in 2025.
  • Its Research & Development was $1.3 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.3 million in Q1 2025.